Cargando…

The role of radiotherapy in pulmonary large cell neuroendocrine carcinoma: propensity score matching analysis

The aim of the study was to investigate the survival advantage of radiotherapy (RT) in patients with pulmonary large cell neuroendocrine carcinoma (LCNEC). Patients with pulmonary LCNEC were extracted from the Surveillance, Epidemiology, and End Results (SEER) dataset between January 2004 and Decemb...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Ling, Wu, Hong-Fen, Zhao, Ling, Bai, Yan, Jiang, Zhi-lan, Yang, Wan-Ju, Liu, Shi-xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336819/
https://www.ncbi.nlm.nih.gov/pubmed/32567658
http://dx.doi.org/10.1093/jrr/rraa036
_version_ 1783554398248501248
author Cao, Ling
Wu, Hong-Fen
Zhao, Ling
Bai, Yan
Jiang, Zhi-lan
Yang, Wan-Ju
Liu, Shi-xin
author_facet Cao, Ling
Wu, Hong-Fen
Zhao, Ling
Bai, Yan
Jiang, Zhi-lan
Yang, Wan-Ju
Liu, Shi-xin
author_sort Cao, Ling
collection PubMed
description The aim of the study was to investigate the survival advantage of radiotherapy (RT) in patients with pulmonary large cell neuroendocrine carcinoma (LCNEC). Patients with pulmonary LCNEC were extracted from the Surveillance, Epidemiology, and End Results (SEER) dataset between January 2004 and December 2013. Propensity score matching (PSM) analysis with 1:1 was used to ensure well-balanced characteristics of all comparison groups. A total of 1480 eligible cases were identified, with a median follow-up time of 11 months (0–131 months). After PSM, 980 patients were classified in no radiotherapy (No RT) and radiotherapy (RT) groups (n = 490 each). Patients in the RT group harbored significantly higher 3- and 5-year overall survival (OS) and cancer-specific survival (CSS) rates compared to those in the No RT group (both P < 0.05). Furthermore, RT was an independent favorable prognostic factor of OS as well as CSS in multivariate analysis, both before [OS: hazard ratio (HR) 0.840, 95% confidence interval (CI) 0.739–0.954, P = 0.007; CSS: HR 0.847, 95% CI 0.741–0.967, P = 0.014] and after (OS: HR 0.854, 95% CI 0.736–0.970, P = 0.016; CSS: HR 0.848, 95% CI 0.735–0.978, P = 0.023) PSM. In subgroup analysis, American Joint Committee on Cancer (AJCC) stage II and III, tumor size 5-10 cm, patients who underwent no surgery, or patients who received chemotherapy could significantly benefit from RT (all P < 0.05). To sum up, our findings suggested that RT could prolong the survival of patients with pulmonary LCNEC, especially those with stage II and III, tumor size 5-10 cm, those with no surgery, or those who received chemotherapy.
format Online
Article
Text
id pubmed-7336819
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-73368192020-07-13 The role of radiotherapy in pulmonary large cell neuroendocrine carcinoma: propensity score matching analysis Cao, Ling Wu, Hong-Fen Zhao, Ling Bai, Yan Jiang, Zhi-lan Yang, Wan-Ju Liu, Shi-xin J Radiat Res Regular Paper The aim of the study was to investigate the survival advantage of radiotherapy (RT) in patients with pulmonary large cell neuroendocrine carcinoma (LCNEC). Patients with pulmonary LCNEC were extracted from the Surveillance, Epidemiology, and End Results (SEER) dataset between January 2004 and December 2013. Propensity score matching (PSM) analysis with 1:1 was used to ensure well-balanced characteristics of all comparison groups. A total of 1480 eligible cases were identified, with a median follow-up time of 11 months (0–131 months). After PSM, 980 patients were classified in no radiotherapy (No RT) and radiotherapy (RT) groups (n = 490 each). Patients in the RT group harbored significantly higher 3- and 5-year overall survival (OS) and cancer-specific survival (CSS) rates compared to those in the No RT group (both P < 0.05). Furthermore, RT was an independent favorable prognostic factor of OS as well as CSS in multivariate analysis, both before [OS: hazard ratio (HR) 0.840, 95% confidence interval (CI) 0.739–0.954, P = 0.007; CSS: HR 0.847, 95% CI 0.741–0.967, P = 0.014] and after (OS: HR 0.854, 95% CI 0.736–0.970, P = 0.016; CSS: HR 0.848, 95% CI 0.735–0.978, P = 0.023) PSM. In subgroup analysis, American Joint Committee on Cancer (AJCC) stage II and III, tumor size 5-10 cm, patients who underwent no surgery, or patients who received chemotherapy could significantly benefit from RT (all P < 0.05). To sum up, our findings suggested that RT could prolong the survival of patients with pulmonary LCNEC, especially those with stage II and III, tumor size 5-10 cm, those with no surgery, or those who received chemotherapy. Oxford University Press 2020-06-22 /pmc/articles/PMC7336819/ /pubmed/32567658 http://dx.doi.org/10.1093/jrr/rraa036 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Regular Paper
Cao, Ling
Wu, Hong-Fen
Zhao, Ling
Bai, Yan
Jiang, Zhi-lan
Yang, Wan-Ju
Liu, Shi-xin
The role of radiotherapy in pulmonary large cell neuroendocrine carcinoma: propensity score matching analysis
title The role of radiotherapy in pulmonary large cell neuroendocrine carcinoma: propensity score matching analysis
title_full The role of radiotherapy in pulmonary large cell neuroendocrine carcinoma: propensity score matching analysis
title_fullStr The role of radiotherapy in pulmonary large cell neuroendocrine carcinoma: propensity score matching analysis
title_full_unstemmed The role of radiotherapy in pulmonary large cell neuroendocrine carcinoma: propensity score matching analysis
title_short The role of radiotherapy in pulmonary large cell neuroendocrine carcinoma: propensity score matching analysis
title_sort role of radiotherapy in pulmonary large cell neuroendocrine carcinoma: propensity score matching analysis
topic Regular Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336819/
https://www.ncbi.nlm.nih.gov/pubmed/32567658
http://dx.doi.org/10.1093/jrr/rraa036
work_keys_str_mv AT caoling theroleofradiotherapyinpulmonarylargecellneuroendocrinecarcinomapropensityscorematchinganalysis
AT wuhongfen theroleofradiotherapyinpulmonarylargecellneuroendocrinecarcinomapropensityscorematchinganalysis
AT zhaoling theroleofradiotherapyinpulmonarylargecellneuroendocrinecarcinomapropensityscorematchinganalysis
AT baiyan theroleofradiotherapyinpulmonarylargecellneuroendocrinecarcinomapropensityscorematchinganalysis
AT jiangzhilan theroleofradiotherapyinpulmonarylargecellneuroendocrinecarcinomapropensityscorematchinganalysis
AT yangwanju theroleofradiotherapyinpulmonarylargecellneuroendocrinecarcinomapropensityscorematchinganalysis
AT liushixin theroleofradiotherapyinpulmonarylargecellneuroendocrinecarcinomapropensityscorematchinganalysis
AT caoling roleofradiotherapyinpulmonarylargecellneuroendocrinecarcinomapropensityscorematchinganalysis
AT wuhongfen roleofradiotherapyinpulmonarylargecellneuroendocrinecarcinomapropensityscorematchinganalysis
AT zhaoling roleofradiotherapyinpulmonarylargecellneuroendocrinecarcinomapropensityscorematchinganalysis
AT baiyan roleofradiotherapyinpulmonarylargecellneuroendocrinecarcinomapropensityscorematchinganalysis
AT jiangzhilan roleofradiotherapyinpulmonarylargecellneuroendocrinecarcinomapropensityscorematchinganalysis
AT yangwanju roleofradiotherapyinpulmonarylargecellneuroendocrinecarcinomapropensityscorematchinganalysis
AT liushixin roleofradiotherapyinpulmonarylargecellneuroendocrinecarcinomapropensityscorematchinganalysis